Key result
Positive antinuclear antibody status was associated with longer relapse-free survival and a lower risk of relapse compared to ANA-negative patients over a median 68-month follow-up.
Why the study?
Do baseline ANA status and concentrations of sFas, sFasL, CXCL8, CXCL10, and CCL20 predict relapses and disability accrual in people with multiple sclerosis?
Cohort (n=42)
Do baseline ANA status and concentrations of sFas, sFasL, CXCL8, CXCL10, and CCL20 predict relapses and disability accrual in people with multiple sclerosis?
ANA positivity and specific chemokine levels may serve as prognostic biomarkers for relapse and disability accrual in multiple sclerosis.
Answers are grounded in this paper and cite their sources.
ANA positivity may indicate lower MS relapse risk; leaves open its role as a validated prognostic biomarker.
BACKGROUND Despite a significant advance in multiple sclerosis (MS) treatment, the lack of reliable and easily available prognostic biomarkers, even with serum NfL and GFAP now available, is more exposed than ever, as they would enable tailoring the therapeutic approach to an individual. Since we earlier demonstrated a link between antinuclear antibodies (ANA) and soluble apoptotic factors sFas and sFasL, as well as between CXCL8 and CXCL10 chemokine levels and MS relapses, these analytes were deemed suitable for longitudinal assessment in this sense. MATERIALS AND METHODS Forty-two people with MS (pwMS) were followed for a median of 68 months, and their initial ANA status, as well as concentrations of sFas, sFasL, CXCL8, CXCL10, and CCL20 were assessed in relation to relapses, disability accrual, and therapy usage during follow up. RESULTS There are fewer pwMS who relapsed amongst those with positive ANA. These subjects had longer relapse-free survival, and lower hazard and odds ratio for relapse compared to ANA-negative pwMS. This was even more pronounced in pwMS with low initial sFasL concentrations, which correlated with higher annualized relapse rate, especially in ANA-negative subjects. CXCL8 concentrations point to a potentially promising sensitivity and specificity for future disability worsening. CONCLUSION ANA presence, alone or in conjunction with sFasL concentrations, could potentially be developed into a prognostic biomarker in pwMS regarding disease activity, while same is true for CXCL8 regarding disability accrual. However, it should be noted that these are exploratory findings requiring external validation. Further studies, especially those with follow-up started at the time of diagnosis, are warranted.
No takes yet. Share an insight, caveat, or question.
Sremec et al. (2026) conducted a cohort in Multiple sclerosis (n=42). Positive antinuclear antibodies (ANA) and biomarker concentrations (sFas, sFasL, CXCL8, CXCL10, CCL20) vs. ANA-negative status was evaluated on Relapses, disability accrual, and therapy usage. Positive antinuclear antibody status was associated with longer relapse-free survival and a lower risk of relapse compared to ANA-negative patients over a median 68-month follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: